On July 30, 2026, the Hong Kong market showed a divergent pattern, with the Hang Seng Index edging down 0.15%, but the pharmaceutical sector rose against the trend, with the Hang Seng Healthcare Index surging 2.8%, becoming the most standout sector of the day. Among them, innovative drug leader BeiGene (06160.HK) soared 7.2%, Innovent Biologics (01801.HK) rose 6.5%, and Akeso (09926.HK) gained 5.9%, driving the entire biotech sector active.
Major Policy Boost: Fast-Track Innovative Drug Approval and Medicare Support
On the news front, on the evening of July 29, the National Medical Products Administration (NMPA) issued "Several Measures on Further Optimizing the Review and Approval of Innovative Drugs," proposing to shorten the clinical trial approval timeline for innovative drugs from 60 working days to 40 working days and establishing fast-track channels such as breakthrough therapy drugs and conditional approvals. Meanwhile, the National Healthcare Security Administration (NHSA) simultaneously signaled that it would study the establishment of a green channel for Medicare access for innovative drugs, with quarterly dynamic adjustments for clinically urgent innovative drugs.
Industry insiders pointed out that this is another major policy catalyst following the 2024 "Full-Chain Support for Innovative Drug Development Implementation Plan." Li Xue, pharmaceutical industry analyst at CICC, said: "This policy directly targets the pain points of long R&D cycles and slow payment recovery for innovative drugs, exerting force from both the review end and the payment end, which is expected to significantly improve the return on investment for innovative drug companies."
Boosted by this, capital inflows into Hong Kong-listed pharmaceutical stocks were notable. According to Wind data, on the morning of July 30, southbound capital net purchased HK$1.86 billion in Hong Kong-listed pharmaceutical stocks, with BeiGene and Innovent Biologics receiving net purchases of HK$420 million and HK$380 million respectively. Capital flows within the sector showed a "broad rise + divergence" pattern: innovative drugs and CXO (pharmaceutical R&D outsourcing) sub-sectors led gains, while traditional generic drug makers performed relatively flat.
Industry Fundamentals: Accelerated Overseas Expansion of Innovative Drugs, Earnings Inflection Point Emerging
Besides short-term policy catalysts, the rise of the Hong Kong-listed pharmaceutical sector also has earnings support. As of the end of July, over 20 Hong Kong-listed pharmaceutical companies have disclosed their 2026 semi-annual report forecasts, with innovative drug companies generally performing well. BeiGene forecast a 45% year-on-year revenue increase in the first half, benefiting from the continued volume expansion of its core product zanubrutinib (Brukinsa) in the U.S. market. Innovent Biologics forecast a turnaround to net profit, mainly from milestone payments from overseas licensing of PD-1 sintilimab.
Notably, the overseas expansion of Chinese innovative drugs has significantly accelerated. In the first half of 2026, three domestic innovative drugs received FDA approval in the U.S., already exceeding the total for 2025. Among them, Akeso's AK112 (ivonescimab) was approved in June for first-line treatment of non-small cell lung cancer, becoming the first domestic bispecific antibody drug approved in the U.S. Pacific Securities research report pointed out that as overseas clinical data continues to be read out, the global market value reassessment space for Hong Kong-listed pharmaceutical leaders is broad.
Fundamental and Technical Analysis: Oversold Rebound or Turning Point?
From a technical perspective, the Hong Kong-listed pharmaceutical sector has cumulatively corrected more than 30% since its 2025 high, with the sector's P/E (TTM) falling back to 18 times, near a five-year low. The volume-up yang line on July 30 broke through the 20-day moving average, with the MACD indicator showing a golden cross signal, indicating a short-term bullish technical pattern.
On the capital front, besides active southbound capital deployment, foreign capital has also shown signs of returning. HKEX disclosure data shows that since July, northbound capital has net purchased approximately HK$5.2 billion in Hong Kong-listed pharmaceutical stocks through the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect, with single-day purchases on July 30 hitting a nearly three-month high. This suggests that against the backdrop of rising global rate cut expectations, capital is re-focusing on reasonably valued growth tracks.
However, some institutions have also flagged risks. Morgan Stanley pointed out that the Hong Kong-listed pharmaceutical sector still faces pressures from the U.S. Biosecurity Act and uncertainties in some companies' R&D pipelines, advising investors to prioritize leading companies with ample cash flow and a high proportion of overseas revenue.
Investment Strategy: Focus on Dual Main Lines of Innovative Drugs and CXO
Looking ahead, many brokerages believe that policy dividends combined with earnings improvements could lead to a phased rebound for the Hong Kong-listed pharmaceutical sector. Guotai Junan recommends focusing on two main lines: first, innovative drug leaders with global capabilities and rich product pipelines, such as BeiGene and Innovent Biologics; second, CXO companies benefiting from order returns from overseas pharmaceutical companies, such as WuXi AppTec (02359.HK) and Pharmaron (03759.HK).
In addition, with the expansion of Stock Connect targets, some small and medium-cap pharmaceutical stocks have also come into the view of southbound capital. Investors can combine their own risk preferences to focus on second-tier innovative drug companies that have achieved commercialization and have strong revenue growth certainty.
Today's strong performance of the Hong Kong-listed biotech sector may be a positive market reaction to the new policy environment. However, it should be noted that the pharmaceutical sector is highly volatile, and investors should remain rational and manage their positions properly.
